Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics Pens Genomic Antibodies Deal With Undisclosed Big Pharma ...

NEW YORK, June 14 (GenomeWeb News) - An undisclosed "top ten" pharmaceutical company has placed an "initial order" with Strategic Diagnostics for its Genomic Antibodies technology, Strategic Diagnostics said today.

 

The company said that scientists fro this drug maker "have unsuccessfully attempted to make antibodies to some of the protein targets in this initial order," which they hope to reverse with Genomic Antibodies.

 

Strategic Diagnostics said this represents the third "major" pharmaceutical customer to initiate a relationship with the company, "and although these represent initially small projects, we are increasingly confident in the commercial viability of this capability."

 

Strategic Diagnostics' most-recent deal before this one was with Berlex in April.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.